Company intelligence / Profile preview

Trimeris, Inc.

Durham, North Carolina, United Statessec.gov ↗

Ownership: Private
Development stage: Commercial

Overview

Trimeris developed Fuzeon (enfuvirtide), an anti-HIV treatment that was commercialized in partnership with Roche. The company also had several preclinical candidates including T-2635 and oligomeric HR2 peptides for HIV, and T-786 and T-118 for respiratory syncytial virus infections, which were discontinued[1][6].

Therapeutic areas: Infectious Diseases
Modalities: Synthetic peptidesFusion inhibitors
Industry: Biotech

Drug pipeline

4 assets

enfuvirtide

Commercial

Indications: HIV infection

3 more assets in the full pipeline.

Request access →

Partnerships

Roche (for Fuzeon development and commercialization)[6]

Beyond the preview

Go deeper on Trimeris, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trimeris, Inc..

Explore the full profile